Examining megakaryocytes in patients with sickle cell disease
Phenotypic and Transcriptomic Description of Megakaryocytes in Sickle Cell Patient
This study looks at how certain blood cells called megakaryocytes behave in people with sickle cell disease to see if they play a role in the complications of the illness.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Toulouse Academic / other |
| Locations | 1 site (Toulouse, France) |
| Trial ID | NCT06887907 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the role of megakaryocytes, the precursors of platelets, in patients with sickle cell disease (SCD). It focuses on understanding how these cells behave in both steady states and during acute complications such as vaso-occlusive crises and acute chest syndrome. By analyzing the phenotypic and transcriptomic characteristics of megakaryocytes, the study seeks to uncover their involvement in the inflammatory and thrombotic processes associated with SCD. The research is conducted at the University Hospital in Toulouse, where patients will be monitored for their megakaryocyte activity.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with sickle cell disease or S-béta° thalassemia, either in a steady state or experiencing acute complications.
Not a fit: Patients with other hematologic disorders or those currently receiving immunosuppressive treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the role of megakaryocytes in sickle cell disease, potentially leading to new therapeutic strategies.
How similar studies have performed: While the role of megakaryocytes in other conditions has been explored, this specific focus on sickle cell disease is relatively novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Sickle cell disease SS or S-béta° thalassemia * Patient at steady state since at least 1 year or at steady state (without crisis), or during vaso-occlusive crisis or during acute chest syndrome * Age \> 18 years old Exclusion Criteria: * Patient objects to take part in the study Hematologic disorder (leukemia, myeloma, myelodysplasic syndrome, myeloproliferative syndrome) * Immune thrombocytopenia, Immunosuppressive or anti-inflammatory (biotherapies, corticosteroids, non steroidal anti-inflammatories drugs) Page 12 sur 23 * Anti-platelets agents * Red blood cell exchange or transfusion \< 3 months
Where this trial is running
Toulouse, France
- CHU de Toulouse — Toulouse, France, France (Recruiting)
Study contacts
- Principal investigator: Pierre COUGOUL, MD — University Hospital, Toulouse
- Study coordinator: Pierre COUGOUL, MD
- Email: cougoul.pierre@iuct-oncopole.fr
- Phone: 0531156265
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.